Alpha Teknova (NASDAQ:TKNO) Releases Earnings Results, Beats Expectations By $0.02 EPS

Alpha Teknova (NASDAQ:TKNO) released its quarterly earnings data on Wednesday. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02, FiscalAI reports. The business had revenue of $12.19 million during the quarter, compared to analyst estimates of $10.96 million. Alpha Teknova had a negative return on equity of 24.32% and a negative net margin of 41.07%.

Here are the key takeaways from Alpha Teknova’s conference call:

• Second-quarter revenue rose 18% to a record $12 million, with growth broad-based across customers and major markets aside from cell and gene therapy. Gross margin improved to 40.1%, while free cash outflow declined sharply to $0.6 million from $2.3 million a year earlier.
• Teknova raised 2026 revenue guidance to $45 million-$47 million, implying approximately 14% growth at the midpoint, and now expects full-year free cash outflow below $8 million.
• Management cited potential longer-term growth from more than 70 therapies and diagnostics in clinical trials, improving biotech funding, and commercial investments, but said the funding benefit has not yet reached revenue and expects most sales impact from the commercial buildout in early 2027.
• Cell and gene therapy demand remains muted, while operating expenses are expected to remain at least $8 million per quarter through year-end. The company still expects adjusted EBITDA to turn positive only after reaching approximately $52 million-$57 million in annualized revenue, and its 2027 target remains in the low-$50-million range.
• The company officially launched Build-Tek, an AI-powered custom-product configurator intended to shorten custom order design from weeks to a few business days and encourage catalog customers to adopt higher-value custom products; management expects it to support growth rather than generate direct software fees.

Alpha Teknova Trading Up 1.6%

Shares of NASDAQ:TKNO traded up $0.09 during mid-day trading on Wednesday, hitting $5.61. The stock had a trading volume of 128,778 shares, compared to its average volume of 185,252. The company’s 50 day moving average is $5.14 and its 200-day moving average is $3.70. Alpha Teknova has a 12-month low of $1.91 and a 12-month high of $6.68. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.60 and a current ratio of 4.59. The company has a market cap of $300.75 million, a PE ratio of -17.53 and a beta of 0.64.

Institutional Trading of Alpha Teknova

Several large investors have recently added to or reduced their stakes in TKNO. XTX Topco Ltd acquired a new stake in shares of Alpha Teknova in the fourth quarter worth $77,000. Marshall Wace LLP lifted its stake in Alpha Teknova by 286.1% in the 4th quarter. Marshall Wace LLP now owns 50,156 shares of the company’s stock worth $191,000 after acquiring an additional 37,164 shares in the last quarter. Jane Street Group LLC purchased a new stake in Alpha Teknova in the 4th quarter worth about $239,000. Kestra Private Wealth Services LLC lifted its stake in Alpha Teknova by 80.3% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 79,648 shares of the company’s stock worth $493,000 after acquiring an additional 35,469 shares in the last quarter. Finally, PharVision Advisers LLC boosted its position in Alpha Teknova by 103.5% during the 3rd quarter. PharVision Advisers LLC now owns 37,645 shares of the company’s stock worth $233,000 after acquiring an additional 19,149 shares during the period. 13.81% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TKNO. Roth Capital initiated coverage on Alpha Teknova in a report on Wednesday. They set a “buy” rating and a $7.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Teknova in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $7.00.

Alpha Teknova Company Profile

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.